Karen F. Kozarsky
Founder at SwanBio Therapeutics, Inc.
Network origin in Karen F. Kozarsky first degree
| Entity | Entity type | Industry | |
|---|---|---|---|
SwanBio Therapeutics, Inc.
 SwanBio Therapeutics, Inc. BiotechnologyHealth Technology SwanBio Therapeutics, Inc. operates as a gene therapy firm. The company was founded by Tom Anderson, Rachel Salzman, Karen Kozarsky and Florian S. Eichler and is headquartered in Bala Cynwyd, PA.
8
| Holding Company | Biotechnology | 8 |
Chart of Companies connected to the second degree
Multi-company connection
Companies connected to Karen F. Kozarsky via their personal network
| Company | Sector | Related people | Main position |
|---|---|---|---|
Alkermes, Inc.
 Alkermes, Inc. Pharmaceuticals: MajorHealth Technology Alkermes, Inc. develops and manufactures pharmaceutical products. It offers medicines for the treatment of central nervous system (CNS) diseases. The company was founded by Michael A. Wall, Floyd E. Bloom, Frederick W. K. Brown, Paul R. Schimmel and Alexander G. Rich in 1987 and is headquartered in Waltham, MA. | Pharmaceuticals: Major | Director of Finance/CFO | |
| AMGEN INC. | Pharmaceuticals: Major | Chief Tech/Sci/R&D Officer | |
| BRISTOL-MYERS SQUIBB COMPANY | Pharmaceuticals: Major | Private Equity Investor | |
| Washington University in St. Louis | College/University | Undergraduate Degree | |
| CUBIST PHARMACEUTICALS INC | Pharmaceuticals: Major | Director/Board Member | |
| MERCK KGAA | Pharmaceuticals: Major | Chief Tech/Sci/R&D Officer | |
| ACADIA PHARMACEUTICALS INC. | Pharmaceuticals: Major | Corporate Officer/Principal | |
Genzyme Corp.
 Genzyme Corp. Medical SpecialtiesHealth Technology Genzyme Corp. engages in development and manufacture of specialty therapeutic, surgical and diagnostic product. It serves in the areas of rare genetic diseases, multiple sclerosis, cardiovascular diseases and endocrinology. The company was founded on June 8, 1981 and is headquartered in Cambridge, MA. | Medical Specialties | Corporate Officer/Principal | |
| ATYR PHARMA, INC. | Pharmaceuticals: Major | Chief Tech/Sci/R&D Officer | |
| NOVARTIS AG | Pharmaceuticals: Major | Chief Tech/Sci/R&D Officer | |
| University of Oxford | College/University | Graduate Degree | |
| University of Cambridge | College/University | Doctorate Degree | |
| ALNYLAM PHARMACEUTICALS, INC. | Pharmaceuticals: Major | Director of Finance/CFO | |
| Brandeis University | College/University | Undergraduate Degree | |
| Colgate University | College/University | Undergraduate Degree | |
| University of California San Diego | College/University | Corporate Officer/Principal | |
| University of Vermont | College/University | Corporate Officer/Principal | |
EMD Serono, Inc.
 EMD Serono, Inc. Pharmaceuticals: MajorHealth Technology EMD Serono, Inc. operates as a biopharmaceutical firm. The firm develops recombinant prescription medicines. Its therapies include neurology and immunology, metabolic endocrinology, fertility, and oncology. The company was founded in 1971 and is headquartered in Rockland, MA. | Pharmaceuticals: Major | Corporate Officer/Principal | |
| Winchester College | College/University | Undergraduate Degree | |
| King's College London | College/University | Undergraduate Degree | |
Novartis Institute for Functional Genomics, Inc.
 Novartis Institute for Functional Genomics, Inc. Miscellaneous Commercial ServicesCommercial Services Novartis Institute For Functional Genomics, Inc. serves as a bridge between basic science and preclinical drug discovery for Novartis’ global research organization. Its focus areas include oncology, autoimmunity, cardiovascular disease, diabetes, musculoskeletal disorders, and infectious disease. The company was founded in 1999 and is headquartered in San Diego, CA. | Miscellaneous Commercial Services | Director/Board Member | |
Novartis Pharma AG
 Novartis Pharma AG Pharmaceuticals: MajorHealth Technology Novartis Pharma AG engages in the research in as well as the production and distribution of pharmaceutical, chemical, medical, and biotechnological products. It also provides related services. The company was founded on October 25, 1989 and is headquartered in Basel, Switzerland. | Pharmaceuticals: Major | Chief Tech/Sci/R&D Officer | |
Deciphera Pharmaceuticals LLC
 Deciphera Pharmaceuticals LLC BiotechnologyHealth Technology Deciphera Pharmaceuticals LLC discovers and develops pharmaceutical preparations. It designs kinase inhibitor therapies that target the hallmarks of cancer biology. The firm’s clinical pipeline of kinase inhibitors includes tumor-targeted therapies and immuno-targeted therapies. It offers DCC-2618, Rebastinib, and DCC-3014. The company was founded by Daniel L. Flynn in 2003 and is headquartered in Waltham, MA. | Biotechnology | Director/Board Member | |
| Bryant University | College/University | Undergraduate Degree | |
| BLUEPRINT MEDICINES CORPORATION | Biotechnology | Director/Board Member | |
Lumos Pharma Sub, Inc.
 Lumos Pharma Sub, Inc. Medical/Nursing ServicesHealth Services Lumos Pharma Sub, Inc. develops and commercializes a novel treatment for the rare disease creatine transporter deficiency. It focuses on bringing novel therapies to patients afflicted with unmet medical needs in severe, rare, and genetic diseases. The firm's technology LUM-001 is a repurposed small molecule that is a kinetically similar analog of creatine and has shown promising therapeutic potential for the treatment of creatine transporter deficiency. Lumos Pharma was founded by Richard J. Hawkins in 2010 and is headquartered in Austin, TX. | Medical/Nursing Services | Chief Tech/Sci/R&D Officer | |
Syncona Partners LLP
 Syncona Partners LLP Investment ManagersFinance Syncona Partners LLP (Syncona Partners) is a venture capital subsidiary of Syncona Investment Management Ltd. founded in 2012 by Martin Murphy. The firm is headquartered in London, United Kingdom. | Investment Managers | Private Equity Investor Private Equity Investor Private Equity Investor | |
| The Wharton School of the University of Pennsylvania | College/University | Masters Business Admin | |
Anokion SA
 Anokion SA Medical/Nursing ServicesHealth Services Anokion SA provides technology for retraining white blood cells to induce therapeutic immune tolerance. The firm?s approach to antigen-specific immune tolerance can be translated to virtually any protein in numerous clinical indications. The company was founded by Jerffery Hubbell, Melody Swartz, Stephan Kontos, Oscar Buset, Kristen M. Lorentz and David A. Lowin and is headquartered in Ecublens, Switzerland. | Medical/Nursing Services | Director/Board Member | |
| Sackler School of Medicine | College/University | Doctorate Degree | |
| University of Louisville School of Medicine | College/University | Doctorate Degree | |
Kanyos Bio, Inc.
 Kanyos Bio, Inc. Pharmaceuticals: MajorHealth Technology Kanyos Bio, Inc. engages in the provision of immune tolerance technology solutions. It develops antigen-specific for treatment of type-1 diabetes and celiac disease. The company was founded by Jeffrey Hubbell, Stephan Kontos, Oscar Buset, Kristen M. Lorentz, and David A. Lowin in 2015 and is headquartered in Cambridge, MA. | Pharmaceuticals: Major | Director/Board Member | |
Yumanity, Inc.
 Yumanity, Inc. Pharmaceuticals: MajorHealth Technology Yumanity, Inc. engages in transforming drug discovery for neurodegenerative diseases services. It provides integrated discovery platforms, phenotypic screening (uHTS) platforms, in which different protein misfolding pathologies are modeled in yeast to help discover compounds to correct these pathologies; a human neuronal platform. The company was founded by Anthony N. Coles, Jr. and Susan L. Lindquist in December 2014 and is headquartered in Boston, MA. | Pharmaceuticals: Major | Director/Board Member | |
Vividion Therapeutics, Inc.
 Vividion Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services Vividion Therapeutics, Inc. operates as a biotechnology company. The company focuses on developing innovative therapeutics that treat major unmet clinical needs using the first platform for proteome wide drug and target discovery. It's proprietary chemoproteomic platform technology addresses the key limitations of conventional screening techniques and allows the discovery of previously unknown, or cryptic, functional pockets on the surface of proteins and identification of small molecules that selectively bind to those targets. The company was founded by Benjamin F. Cravatt, Phil S. Baran, Jin-Quan Yu and John K. Clarke on December 24, 2013 and is headquartered in San Diego, CA. | Miscellaneous Commercial Services | Director of Finance/CFO | |
| DECIPHERA PHARMACEUTICALS, INC. | Biotechnology | Director/Board Member | |
Inversago Pharma, Inc.
 Inversago Pharma, Inc. Pharmaceuticals: MajorHealth Technology Inversago Pharma, Inc. develops novel gastrointestinal drugs. The company was founded by Fran?ois Ravenelle in and is headquartered in Montreal, Canada. | Pharmaceuticals: Major | Director/Board Member | |
Anaveon AG
 Anaveon AG BiotechnologyHealth Technology Anaveon AG engages in the development of immune therapies against cancer. Its compounds promote effector T-cell functions to enhance a patient?s immune system to respond to tumors. The company was founded on December 11, 2017 by Onur Boyman and Andreas Katopodis and is headquartered in Bottmingen, Switzerland. | Biotechnology | Director/Board Member | |
AxoSim, Inc.
 AxoSim, Inc. Packaged SoftwareTechnology Services Axosim, Inc. operates as a biotechnology company that develops nerve-on-a-chip platform. The company was founded by Lowry Curley and Michael Moore and is headquartered in New Orleans, LA. | Packaged Software | Chairman | |
| BRIGHT MINDS BIOSCIENCES INC. | Biotechnology | Director/Board Member | |
| Bluerock Therapeutics, Inc. | Director/Board Member | ||
| CHEMOMAB THERAPEUTICS LTD. | Biotechnology | Chief Tech/Sci/R&D Officer | |
| Forcefield Therapeutics Ltd. | Chief Executive Officer | ||
| BIOSURGERY S.R.L. | Corporate Officer/Principal | ||
| UB School of Medicine & Biomedical Sciences | College/University | Doctorate Degree | |
| AYTU BIOPHARMA, INC. | Pharmaceuticals: Major | Chief Operating Officer |
Statistics
International
| United States | 36 |
| United Kingdom | 7 |
| Switzerland | 5 |
| Israel | 3 |
| Germany | 2 |
Sectoral
| Health Technology | 27 |
| Consumer Services | 15 |
| Commercial Services | 3 |
| Health Services | 3 |
| Finance | 3 |
Operational
| Director/Board Member | 30 |
| Corporate Officer/Principal | 15 |
| Independent Dir/Board Member | 11 |
| Chief Tech/Sci/R&D Officer | 9 |
| Chief Operating Officer | 6 |
Most connected contacts
| Insiders | |
|---|---|
| Alison Lawton | 25 |
| Patricia Allen | 14 |
| David Weiner | 14 |
| John Tsai | 10 |
| Alex Hamilton | 6 |
| Danny Bar-Zohar | 5 |
| Christopher Brooke | 5 |
| Rachel Lynn Salzman | 1 |
- Stock Market
- Insiders
- Karen F. Kozarsky
- Company connections
